Physician profile
Seth M Keller
NPI 1366557043
$27,394.41
in general payments reported to CMS, 2019-2025
71 companies · $3,348 in 2025
The $3,348 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,403 · 2020: $483 · 2021: $1,797 · 2022: $2,319 · 2023: $9,129 · 2024: $7,916 · 2025: $3,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $11K · Food and Beverage: $6,859 · Travel and Lodging: $1,191 · Consulting Fee: $1,187 · Education: $76.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $11,080.00 |
| Food and Beverage | $6,858.92 |
| Travel and Lodging | $1,190.89 |
| Consulting Fee | $1,186.50 |
| Education | $76.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $12,936.45 | 2023-2024 | Fycompa |
| Jazz Pharmaceuticals INC. | $1,452.09 | 2022-2025 | |
| Biogen, INC. | $1,382.58 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Emd Serono, INC. | $1,293.62 | 2019-2025 | Mavenclad |
| Abbvie INC. | $1,040.95 | 2019-2025 | |
| Ucb, INC. | $915.24 | 2019-2025 | Fintepla, Briviact, Rystiggo |
| Pfizer INC. | $664.74 | 2023-2025 | |
| Sk Life Science, INC. | $632.87 | 2021-2025 | Xcopri |
| Lilly USA, LLC | $607.82 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Validus Pharmaceuticals LLC | $520.18 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $361.84 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $353.77 | 2019-2025 | Ultomiris |
| Sunovion Pharmaceuticals INC. | $334.19 | 2019-2022 | |
| Eisai INC. | $309.96 | 2019-2023 | |
| W. L. Gore & Associates, INC. | $253.08 | 2019-2025 | Gore Cardioform Septal Occluder |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.